Phaseline

Targets › PDCD1L2

PDCD1L2 (Programmed cell death 1 ligand 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.

Plays a critical role in induction and maintenance of immune tolerance to self. Acts as a ligand for the inhibitory receptor PDCD1/PD-1, inhibiting T-cell proliferation by blocking cell cycle progression and cytokine production. (UniProt, Q9BQ51)

Open in Phaseline: the race on PDCD1L2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tianjin Medical University Cancer Institute and HospitalIvonescimab (AK112)
PD-1/PD-L2 dual checkpoint inhibitor
PDCD1L2, PDCD1Phase 2ESCCAug 2027

Conditions

ESCC (1)

Modalities

antibody (1)

Companies

Tianjin Medical University Cancer Institute and Hospital (1)

Related targets

PDCD1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.